Pradaxa（达比加群酯）是口服直接凝血酶抑制剂，去年10月被美国FDA批准。与传统抗凝药华法林相比，Pradaxa可以显著降低非瓣膜性房颤患者卒中和系统性栓...
基于756个网页-相关网页
Pradaxa（达比加群）是首个获长期临床数据支持的新型口服抗凝药，用于成年非瓣膜性心房颤动患者的卒中和全身性栓塞预防。
基于386个网页-相关网页
2008年7月，英国国立健康和临床规范研究所推荐将泰毕全（Pradaxa）作为VTE一级预防的治疗选择。在达到这些重要的里程碑之后，达比加群还在全球80多个国家被批准用于接受择期全髋关节或择期全膝关节...
基于44个网页-相关网页
Pradaxa mesylate 达比加群酯甲磺酸盐
Pradaxa, from Boehringer Ingelheim, was approved by the Food and Drug Administration last October.
FORBES: A Victory For Pfizer And Bristol-Myers Squibb
The most likely outcome: Pradaxa gets approved at both doses, but with a weak label.
FORBES: The $12 Billion Battle At Pharma's Bleeding Edge
The letter will inform physicians that Pradaxa is now contraindicated in patients with mechanical heart valves.
FORBES: Pradaxa To Be Contraindicated In Patients With Mechanical Heart Valves
应用推荐
模块上移
模块下移
不移动